Cidara Therapeutics Inc’s filing revealed that its Director RA CAPITAL MANAGEMENT, L.P. acquired Company’s shares for reported $100.0 million on Jun 26 ’25. In the deal valued at $44.00 per share,2,272,727 shares were bought. As a result of this transaction, RA CAPITAL MANAGEMENT, L.P. now holds 3,365,523 shares worth roughly $162.55 million.
Then, Mineo Chrysa bought 2,270 shares, generating $49,281 in total proceeds. Upon buying the shares at $21.71, the Director now owns 2,270 shares.
Before that, Mineo Chrysa bought 1,050 shares. Cidara Therapeutics Inc shares valued at $24,614 were divested by the Director at a price of $23.44 per share. As a result of the transaction, Mineo Chrysa now holds 3,320 shares, worth roughly $0.16 million.
A number of analysts have revised their coverage, including Citizens JMP’s analysts, who began to cover the stock in mid March with a ‘”a Mkt outperform”‘ rating. RBC Capital Mkts started covering the stock on December 13, 2024. It rated CDTX as “an Outperform”.
Price Performance Review of CDTX
On Monday, Cidara Therapeutics Inc [NASDAQ:CDTX] saw its stock fall -0.98% to $48.3. Over the last five days, the stock has lost -2.33%. Cidara Therapeutics Inc shares have risen nearly 304.86% since the year began. Nevertheless, the stocks have risen 79.69% over the past one year. While a 52-week high of $56.83 was reached on 06/24/25, a 52-week low of $10.14 was recorded on 04/07/25.
Levels Of Support And Resistance For CDTX Stock
The 24-hour chart illustrates a support level at 46.42, which if violated will result in even more drops to 44.54. On the upside, there is a resistance level at 49.35. A further resistance level may holdings at 50.39.
How much short interest is there in Cidara Therapeutics Inc?
A steep rise in short interest was recorded in Cidara Therapeutics Inc stocks on 2025-06-13, growing by 0.2 million shares to a total of 0.65 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 0.45 million shares. There was a rise of 31.31%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 08, 2024 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $33 price target.
